Zavicefta: Additional Ph III REPROVE data
Additional data from the double-blind, double-dummy, international Phase III REPROVE trial in 879 patients with HAP, including VAP, showed that 2,000 mg/500 mg IV Zavicefta ceftazidime/avibactam as a 2-hour infusion every 8 hours led to clinical cure rates of 68.8% and 77.4% in the clinically mITT and clinically evaluable populations, respectively, at the TOC visit 21-25 days after randomization vs. 73% and 78.1% for IV meropenem. Data were presented at the European Congress of Clinical Microbiology and Infectious Diseases in Vienna. Previously reported top-line data showed that Zavicefta met the co-primary endpoints of non-inferiority to IV meropenem in improving clinical cure rate at the TOC visit in the clinically mITT and clinically evaluable populations (see BioCentury, Aug. 1, 2016)...
BCIQ Target Profiles